Healthcare Economics is Front and Center at both Rice and Carnegie Mellon Tepper ChaptersDecember 11, 2015
From the controversy in the mainstream press surrounding Turing Pharmaceuticals to the discussions surrounding the ongoing implementation of the Affordable Care Act, healthcare continues to be a major concern among both the business community and the population at large. Recent Adam Smith Society events, hosted by two of our on-campus chapters, provided MBA students and their university communities with perspectives on a variety of issues surrounding healthcare and business.
On December 1 at Rice University’s Jones School of Business, the Rice chapter of the Adam Smith Society held a cordial debate on drug pricing. Using the controversy growing out of Turing Pharmaceuticals raising the price of its drug, Darapirm, the chapter invited Vivian Ho, Ph.D., the Director of the Center for Health and Biosciences at Rice’s James A. Baker III Institute, and Yevgeniy Feyman, a Fellow and Deputy Director of Health Policy for the Manhattan Institute to debate and discuss the question of whether the government should regulate prescription drug prices.
On December 10 at Carnegie Mellon University’s Tepper School of Business, the Adam Smith Society chapter hosted a wide-ranging discussion about healthcare economics and policy. The debate, entitled, “Where Do We Go from Here?” again included the Manhattan Institute’s Yevgeniy Feyman and Carnegie Mellon’s Martin S. Gaynor, Ph.D., E.J. Barone Professor of Economics and Health Policy and Chair of the Governing Board of the Health Care Cost Institute. The event was co-hosted by the Tepper School of Business’s Healthcare Club.